29,329 results match your criteria myeloma patients


Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma.

Transplant Cell Ther 2021 Apr 17;27(4):310.e1-310.e6. Epub 2020 Dec 17.

Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

Adaptive natural killer (NK) cells are long-lived and exhibit properties of immunologic memory against cytomegalovirus (CMV). We previously reported that expansion of adaptive NK cells after CMV reactivation in recipients of allogeneic hematopoietic cell transplantation (HCT) was associated with a lower rate of relapse of acute myelogenous leukemia. In the present study, we examined the impact of adaptive NK cell expansion in a cohort of 110 individuals who underwent autologous HCT (AHCT) for a lymphoid malignancy (lymphoma or multiple myeloma [MM]). Read More

View Article and Full-Text PDF

Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma.

Transplant Cell Ther 2021 Apr 17;27(4):309.e1-309.e5. Epub 2020 Dec 17.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address:

Patients who undergo autologous stem cell transplantation (ASCT) for multiple myeloma (MM) are routinely assessed at day +100 using serum and urine protein electrophoresis/immunofixation and the serum free light chain (sFLC) assay. We evaluated whether an increase in M-spike or FLC from immediately before ASCT to day +100 post-ASCT has any prognostic impact. We retrospectively reviewed 1218 patients with MM at the Mayo Clinic who underwent their first ASCT between 2000 and 2016. Read More

View Article and Full-Text PDF

Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a analysis of phase 3 clinical trials.

Leuk Lymphoma 2021 Apr 9:1-8. Epub 2021 Apr 9.

Department of Internal Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, USA.

It is unknown if daratumumab could affect venous thromboembolism (VTE) risks in patients with multiple myeloma (MM). In this study, individual participant data from three trials comparing daratumumab (DARA) and non-DARA regimens, the CASTOR, PULLOX and MAIA trial, were pooled into two groups. A total of 896 and 899 patients received DARA and non-DARA regimens, respectively. Read More

View Article and Full-Text PDF

Disruptive technologies for hemodialysis: medium and high cutoff membranes. Is the future now?

J Bras Nefrol 2021 Apr 9. Epub 2021 Apr 9.

San Bortolo Hospital, International Renal Research Institute of Vicenza, Department of Nephrology, Dialysis and Transplantation, Vicenza, Italy.

In the past decade, a new class of hemodialysis (HD) membranes (high retention onset class) became available for clinical use. The high cutoff (HCO) and the medium cutoff (MCO) membranes have wider pores and more uniformity in pore size, allowing an increased clearance of uremic toxins. Owing to the mechanism of backfiltration/internal filtration, middle molecules are dragged by the convective forces, and no substitution solution is needed. Read More

View Article and Full-Text PDF

Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma.

Front Oncol 2021 23;11:563384. Epub 2021 Mar 23.

Department of Experimental and Clinical Oncology, Discipline of Hematology and Hemotherapy, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.

Although the "seed and soil" hypothesis was proposed by Stephen Paget at the end of the 19th century, where he postulated that tumor cells (seeds) need a propitious medium (soil) to be able to establish metastases, only recently the tumor microenvironment started to be more studied in the field of Oncology. Multiple myeloma (MM), a malignancy of plasma cells, can be considered one of the types of cancers where there is more evidence in the literature of the central role that the bone marrow (BM) microenvironment plays, contributing to proliferation, survival, migration, and drug resistance of tumor cells. Despite all advances in the therapeutic arsenal for MM treatment in the last years, the disease remains incurable. Read More

View Article and Full-Text PDF

Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.

Transplant Cell Ther 2021 Mar 6. Epub 2021 Mar 6.

Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.

Preemptive administration of tocilizumab (toci) to manage cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) therapy may reduce rates of serious CRS but conversely may worsen neurotoxicity or risk of infections. Optimal toci administration strategies for patients with relapsed/refractory multiple myeloma (RRMM) receiving B cell maturation antigen (BCMA)-directed CAR-T therapies have not been evaluated. The objective of this study was to identify whether shorter time-to-toci intervals (hours between first fever attributed to CRS and first dose of toci) have any impact on therapy-related toxicities or clinical outcomes among patients with RRMM receiving BCMA-directed CAR-T therapies. Read More

View Article and Full-Text PDF

[Multiple myeloma in an elderly patient with history of breast cancer : the value of multidisciplinary oncogeriatric collaboration].

Rev Med Liege 2021 Apr;76(4):232-238

Service de Gériatrie, CHR Citadelle, Liège, Belgique.

As the prevalence of cancers increases with age, some elderly patients are confronted with multiple tumoural pathologies. The clinical case of a 70-year-old patient with adenocarcinoma of the breast and multiple myeloma complicated by severe renal failure illustrates the complexity of oncogeriatric management. The geriatric assessment makes it possible to detect frailty and provides assistance in the development of a personalized care plan while respecting the quality of life. Read More

View Article and Full-Text PDF

[Hypomagnesemia induced by gastrointestinal losses due to carfilzomib].

Rinsho Ketsueki 2021 ;62(3):190-192

Depertment of Hematology, Fuchu Hospital.

A 67-year-old man with multiple myeloma had been treated with carfilzomib, lenalidomide, and dexamethasone (KRd) therapy. During the second course, he developed dyspnea, which gradually worsened. After admission, gastrointestinal losses of magnesium were confirmed, and intravenous magnesium was administered, which consequently improved his symptoms. Read More

View Article and Full-Text PDF

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.

Blood 2021 Apr 7. Epub 2021 Apr 7.

institut universitaire du cancer toulouse oncopole, toulouse, France.

Bortezomib, lenalidomide, dexamethasone plus transplant is a standard of care for eligible Multiple Myeloma patients. As responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In this phase II study, patients received eight 28-day cycles of carfilzomib (K) 20/36mg/m2 (D1-2,8-9,15-16), lenalidomide (R) 25 mg (D1-21), and dexamethasone (d) 20 mg (D1-2,8-9,15-16,22-23). Read More

View Article and Full-Text PDF

Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study.

Br J Gen Pract 2021 Apr 6. Epub 2021 Apr 6.

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Background: Patients with myeloma experience substantial delays in their diagnosis, which can adversely affect their prognosis.

Aim: To generate a clinical prediction rule to identify primary care patients who are at highest risk of myeloma.

Design And Setting: Retrospective open cohort study using electronic health records data from the UK's Clinical Practice Research Datalink (CPRD) between 1 January 2000 and 1 January 2014. Read More

View Article and Full-Text PDF

Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.

Br J Haematol 2021 Apr 6. Epub 2021 Apr 6.

Janssen Global Services, Raritan, NJ, USA.

In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone (Rd) alone. Here, we present patient-reported outcomes (PROs) from POLLUX, assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaires. Changes from baseline are presented as least-squares mean changes with 95% confidence intervals (CIs) derived from a mixed-effects model. Read More

View Article and Full-Text PDF

The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.

Blood Adv 2021 Apr;5(7):1933-1946

Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC.

Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels of fatty acid elongase 6 (ELOVL6) were lower in MM cells from BTZ-nonresponsive vs BTZ-responsive patients and in cultured MM cells selected for BTZ resistance compared with parental counterparts. Read More

View Article and Full-Text PDF

Optimising cardiovascular care of patients with multiple myeloma.

Heart 2021 Apr 5. Epub 2021 Apr 5.

Department of Cardio-Oncology, St Bartholomew's Hospital, London, UK

Multiple myeloma (MM) is the third most common haematological malignancy, with increasing prevalence over recent years. Advances in therapy have improved survival, changing the clinical course of MM into a chronic condition and meaning that management of comorbidities is fundamental to improve clinical outcomes. Cardiovascular (CV) events affect up to 7. Read More

View Article and Full-Text PDF

Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Thromb Res 2021 Mar 21;202:108-118. Epub 2021 Mar 21.

Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address:

Background: Multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of thrombotic events, especially during anti-myeloma treatment. Many different underlying causes for this hypercoagulability have been suggested, but current techniques to identify abnormalities in these patients are sparse and inefficient. The aim of this study was to assess the hypercoagulability in MGUS and MM patients through various coagulation analyses and identify changes in the MM patients throughout their treatment regimen. Read More

View Article and Full-Text PDF

Infections in hematopoietic stem cell transplant patients admitted to Hematology intensive care unit: a single-center study.

Hematology 2021 Dec;26(1):328-339

Department of Internal Medicine, Division of Hematology, Gazi University Faculty of Medicine, Ankara, Turkey.

Objective: The aim of this study was to investigate the data of HSCT patients who were admitted to our Hematology ICU due to infections or infectious complications.

Materials And Methods: HSCT patients who were admitted to our Hematology ICU between 01 January 2014 and 01 September 2017 were analyzed retrospectively.

Results: 62 HSCT patients were included in this study. Read More

View Article and Full-Text PDF
December 2021

A 65-Year-Old Man With Back Pain and Imaging Findings of Spinal Cord Compression.

Oncology (Williston Park) 2021 Mar;35(3):128-133

Midwest Imaging Interventional Radiology, Grand Island, Nebraska.

Spinal cord compression is a potentially devastating consequence of cancer. Early recognition of the signs and symptoms permit diagnosis prior to the development of irreversible neurological damage. This complication occurs in 5% to 10% of patients with malignancy, often at the end stages of the patient's illness; however, it can be the presenting manifestation of malignancy in up to 23% of patients. Read More

View Article and Full-Text PDF

Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway.

Open Life Sci 2020 9;15(1):284-295. Epub 2020 Jun 9.

Department of Hematology, Ji'ning No. 1 People's Hospital, Ji'ning, Shandong, China.

Multiple myeloma (MM) is a serious health issue in hematological malignancies. Long non-coding RNA taurine-upregulated gene 1 (TUG1) has been reported to be highly expressed in the plasma of MM patients. However, the functions of TUG1 in MM tumorigenesis along with related molecular basis are still undefined. Read More

View Article and Full-Text PDF

Pros and Cons for Fluorescent Hybridization, Karyotyping and Next Generation Sequencing for Diagnosis and Follow-up of Multiple Myeloma.

Balkan J Med Genet 2020 Nov 23;23(2):59-64. Epub 2021 Mar 23.

Department of Hematology, Faculty of Medicine, Trakya University, Edirne, Turkey.

Multiple myeloma (MM) is one of the plasma cell-related hematological malignancies exceeding 10.0% of all marrow cells, and they make a paraprotein that is a marker of the disease. Myeloma is one of the most common types of hematological malignancies in humans. Read More

View Article and Full-Text PDF
November 2020

The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.

Cureus 2021 Feb 25;13(2):e13552. Epub 2021 Feb 25.

Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Immunotherapy is the upcoming trend in cancer treatment. Traditional cancer treatment methods include surgical resection, radiotherapy, chemotherapy, small molecule targeted drugs, monoclonal antibodies, and hematopoietic stem cell transplantation (HSCT). Surgical resection is useful for early-stage patients but not for metastatic cancer cells; radiotherapy and chemotherapy are more common but produce substantial damage to normal tissues and have poor selectivity. Read More

View Article and Full-Text PDF
February 2021

Pregnancy and Its Successful Outcome in a Patient with Multiple Myeloma.

J Obstet Gynaecol India 2021 Feb 10;71(1):78-81. Epub 2020 Jan 10.

Department of Hematology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh 226014 India.

Multiple myeloma is a B-cell neoplastic disorder and represents 1% of all cancers and 13% of hematological malignancies. It is predominantly a disease of elderly, and less than 3% of all cases are below the age of 40 years. We present the case of a 29-year-old lady with multiple myeloma who had spontaneous conception during maintenance therapy and subsequently a successful pregnancy outcome. Read More

View Article and Full-Text PDF
February 2021

Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population.

Clin Lymphoma Myeloma Leuk 2021 Mar 4. Epub 2021 Mar 4.

Leukemia/BMT Program of British Columbia, Vancouver General Hospital, Vancouver, Canada. Electronic address:

Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend to have few comorbidities suggesting their EM is owing to aggressive underlying disease. We sought to characterize this ultra-high risk population through a retrospective review of patients with newly diagnosed multiple myeloma (MM) treated with first-line ASCT. Read More

View Article and Full-Text PDF

Pulmonary infection with Penicillium citrinum in a patient with multiple myeloma.

Indian J Med Microbiol 2021 Apr 1. Epub 2021 Apr 1.

Department of Microbiology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.

A 60-year-old male patient undergoing chemotherapy for multiple myeloma Stage II presented to our hospital with complaints of cough, haemoptysis, fever and loose stools. Sputum sample was sent for fungal culture. Fungal culture on Sabouraud dextrose agar yielded bluish-green velvety growth with orange-to-red diffusible pigment on the reverse. Read More

View Article and Full-Text PDF

Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment.

Semin Ultrasound CT MR 2021 Apr 30;42(2):184-193. Epub 2020 Aug 30.

Department of Musculoskeletal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

Multiple myeloma is a common hematologic malignancy of plasma cells. Differentiating multiple myeloma from the precursor stages of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma is very important because the treatment approach is different for each. The diagnosis is mainly clinical, while the role of imaging is confined to the staging process, assessing response to therapy, and monitoring for disease progression. Read More

View Article and Full-Text PDF

[Expression of CD56 in Multiple Myeloma Cells and Its Relationship with Extramedullary Disease and Extramedullary Relapse].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):553-556

Department of Hematology, Gansu Provincial Hospital; Lanzhou 730000, Gansu Province, China,E-mail:

Objective: To investigate the expression of CD56 in multiple myeloma (MM) cells and its relationship between extramedullary disease and extramedullary relapse.

Methods: Clinical data of 99 patients with MM treated in our hospital from January 2015 to December 2019 was retrospectively analyzed. The patients were divided into positive group and negative group according to the expression of CD56. Read More

View Article and Full-Text PDF

[Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):547-552

Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.

Objective: To explore the clinical features, prognosis and survival of patients with IgD multiple myeloma (MM).

Methods: The clinical data of 20 patients with IgD MM was analyzed retrospectively. The prognostic factors and survival analysis was carried out. Read More

View Article and Full-Text PDF

[Evaluation of the Clinical Efficacy and Prognosis of Long-Term Maintenance Lenalidomide Therapy in Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):540-546

Department of Oncology, Shunde Hospital, Guangzhou University of Chinese Medicine, Shunde 528333, Guangdong Province,

Objective: To investigate the clinical efficacy and prognosis of patients with multiple myeloma (MM) treated by long-term maintenance lenalidomide treatment.

Methods: A total of 97 patients diagnosed as MM in the Department of Hematology of First Affiliated Hospital of Guangzhou University of Chinese Medicine from 2012 to 2019 were selected, and the basic clinical characteristics and laboratory indicators of the patients were tested and evaluated. After long-term maintenance lenalidomide treatment for patients with MM, the short-term and long-term clinical efficacy and the incidence of adverse reactions were evaluated, and factors affecting the prognosis of the patients were analyzed. Read More

View Article and Full-Text PDF

[The Prognostic Value of Early Relapse after Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):535-539

Department of Hematology, Affiliated Shanxi Bethune Hospital of Shanxi Medical University, Taiyuan 030032, Shanxi Province, China,E-mail:

Objective: To assess the impact of early relapse (ER) after autologous hematopoietic stem cell transplan-tation (AHSCT) on overall survival (OS) for multiple myeloma (MM) patients.

Methods: Clinical data of 37 patients with MM undergoing AHSCT in department of hematology of Shanxi Bethune Hospital from January 2012 to December 2017 were retrospectively analyzed. The effect of ER on OS of patients was analyzed. Read More

View Article and Full-Text PDF

[The Influence of Serum Homocysteine Level to the Prognosis of Newly Diagnosed Multiple Myeloma Patients and Analysis of Related Factors].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):530-534

Department of Hematology,Gansu Provincial Hospital,Lanzhou 730700,Gansu

Objective: To analyze the influence of serum homocysteine (Hcy) levels to the prognosis of newly diagnosed multiple myeloma (MM) patients, and to explore related factors affecting the prognosis of the patients.

Methods: The clinical pathological data of 180 newly diagnosed MM patients treated in our hospital from March 2013 to February 2015 were collected, and the patients were divided into high and low Hcy groups based on the median Hcy. The survival curves of the patients in the two groups were drawn to compare the differences of the survival; univariate and multivariate survival analysis was used to observe the influence of serum cysteine to the prognosis of newly diagnosed MM patients; the clinicopathological data of the patients with high and low Hcy in the two groups was compared, Pearson test was used to further analyzes the relationship between Hcy and different factors, and explores the related factors of Hcy affecting the prognosis of the patients. Read More

View Article and Full-Text PDF

[Expression and Clinical Significance of Heat Shock Protein 90 in Multiple Myeloma Patients].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):525-529

Fujian Insitute of Hematology, Fujian Provincial Key Laboratory of Hematology, FUjian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China,E-mail:

Objective: To investigate the expression of HSP90 in bone marrow samples of multiple myeloma (MM) patients and explore its clinical significance.

Methods: Maxvision immunohistochemistry technique was used to detect the protein expression level of HSP90 76 MM patients and 29 normal healthy donors. The clinical characteristics of the patients were collected, and the correlation between the HSP90 expression and the clinical characteristics was analyzed. Read More

View Article and Full-Text PDF

[Analysis of Serum Metabonomics in Patients with Multiple Myeloma Based on Liquid Chromatography-Mass Spectrometry].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Apr;29(2):520-524

Department of Hematology, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, Jiangsu Province, China,E-mail:

Objective: To observe the changes of serum metabolites in patients with multiple myeloma (MM) by metabonomics, and explore the potential biomarkers for diagnosis, prognosis, and progression of MM.

Methods: Serum samples were collected from 26 patients with MM and 50 healthy controls. The data detected by liquid chromatography-mass spectrometry (LC-MS) was input into SIMCA-14. Read More

View Article and Full-Text PDF